SCHEMBL16184223

SCHEMBL16184223

Fc1ccc(-c2ccc3c(N4CCC4)nc(-c4cnccn4)nc3c2)c(F)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALOX5AP P20292 3/20 0.41
▸ FEN1 P39748 2/20 0.41
▸ TSHR P16473 3/20 0.41
▸ LMNA P02545 3/20 0.41
▸ RAB9A P51151 3/20 0.41
▸ MAPK1 P28482 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ TDP1 Q9NUW8 2/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ METAP1 P53582 1/20 0.41
▸ MAPT P10636 3/20 0.40
▸ USP2 O75604 2/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ PIK3CA P42336 4/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ HIF1A Q16665 2/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ GBA1 P04062 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16184229 0.93 TSHR (0.40) ALOX5APFEN1TSHRLMNARAB9A
SCHEMBL16184234 0.90 HIF1A (0.51) ALOX5APFEN1TSHRLMNARAB9A
SCHEMBL16184221 0.90 TSHR (0.44) TSHRLMNARAB9AMAPK1KMT2A
SCHEMBL16184244 0.87 LMNA (0.45) TSHRLMNARAB9AMAPK1KMT2A
SCHEMBL16184230 0.87 TSHR (0.43) TSHRLMNARAB9AMAPK1KMT2A
SCHEMBL16184235 0.87 TSHR (0.43) TSHRLMNARAB9AMAPK1KMT2A
SCHEMBL16184222 0.86 HIF1A (0.44) ALOX5APFEN1TSHRLMNARAB9A
SCHEMBL16184226 0.85 TSHR (0.58) TSHRLMNAMAPK1KMT2AMAPT
SCHEMBL16184236 0.82 LMNA (0.54) TSHRLMNARAB9AMAPK1KMT2A
SCHEMBL16184020 0.81 ALOX5AP (0.36) ALOX5APFEN1RAB9ANPC1GBA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB ALOX5AP 2918/4885FEN1 3258/4885TSHR 2280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback